Skip to Content
Merck
  • A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction.

A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction.

Journal of addictive diseases (2013-03-14)
Anne M Neumann, Richard D Blondell, Urmo Jaanimägi, Amanda K Giambrone, Gregory G Homish, Jacqueline R Lozano, Urszula Kowalik, Mohammadreza Azadfard
ABSTRACT

Patients with opioid addiction who receive prescription opioids for treatment of nonmalignant chronic pain present a therapeutic challenge. Fifty-four participants with chronic pain and opioid addiction were randomized to receive methadone or buprenorphine/naloxone. At the 6-month follow-up examination, 26 (48.1%) participants who remained in the study noted a 12.75% reduction in pain (P = 0.043), and no participants in the methadone group compared to 5 in the buprenorphine group reported illicit opioid use (P = 0.039). Other differences between the two conditions were not found. Long-term, low-dose methadone or buprenorphine/naloxone treatment produced analgesia in participants with chronic pain and opioid addiction.

MATERIALS
Product Number
Brand
Product Description

Supelco
Naloxone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Naloxone hydrochloride dihydrate, ≥98% (TLC and titration), powder